Specifically, troglitazone could synergize with cisplatin or paclitaxel to inhibit NSCLC both in vitro and in vivo in a sequence-specific manner, while rosiglitazone combination with carboplatin reduced the growth of KRAS- or EGFR-mutated lung cancers [109,110]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.